(Q38428919)

3 September 2017

title

Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck (English)

1 reference

metastatic squamous cell carcinoma

3 September 2017

main subject

1 reference

Patricia A Tang

1

1 reference

3 September 2017

Lillian L Siu

2

1 reference

3 September 2017

Eric X Chen

3

1 reference

3 September 2017

Sebastien J Hotte

4

1 reference

3 September 2017

Stephen Chia

5

1 reference

3 September 2017

James K Schwarz

6

1 reference

3 September 2017

Gregory R Pond

7

1 reference

3 September 2017

Caitlin Johnson

8

1 reference

3 September 2017

A Dimitrios Colevas

9

1 reference

3 September 2017

Timothy W Synold

10

1 reference

3 September 2017

Lakshmi S Vasist

11

1 reference

3 September 2017

Eric Winquist

12

1 reference

3 September 2017

language of work or name

1 reference

24 November 2007

1 reference

Investigational New Drugs

3 September 2017

published in

1 reference

3 September 2017

volume

26

1 reference

3 September 2017

issue

3

1 reference

3 September 2017

page(s)

257-264

1 reference

Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma

3 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-007-9098-8

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

12 December 2020

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

12 December 2020

Antitumor activity of a kinesin inhibitor

1 reference

12 December 2020

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Chemotherapy for head and neck cancer. Comparison of cisplatin + vinblastine + bleomycin versus methotrexate

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

1 reference

12 December 2020

Past and future of the mitotic spindle as an oncology target

1 reference

12 December 2020

A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group

1 reference

12 December 2020

The way things move: looking under the hood of molecular motor proteins

1 reference

12 December 2020

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy.

1 reference

12 December 2020

10.1007/S10637-007-9098-8

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1047704640

0 references

1 reference